The emergence of mephedrone and other artificial cathinones has presented difficulties for lawmakers and regulatory businesses tasked with controlling the proliferation of recent psychoactive substances. The dynamic nature of synthetic drug output, coupled with the ability of chemists to change molecular constructions to evade legal limits, complic